ROLE AND ELEVATING PROGNOSTIC PRECISION OF PIVKA-II AS A SUPERIOR BIOMARKER IN HCC DIAGNOSIS, SURPASSING AFP

M YASEEN; R ANWAR; MM AHMAD; H JAVAID; M SADIA; MR BUTT

doi:10.54112/bcsrj.v2024i1.695

Authors

M YASEEN Department of Allied Health Sciences, College of Rehabilitation Sciences, Government College University Faisalabad- Pakistan
R ANWAR Faculty of Rehabilitation and Allied Health Sciences (FRAHS), Riphah International University Faisalabad, Pakistan
MM AHMAD Faculty of Life Sciences, Government College University Faisalabad, Pakistan
H JAVAID Faculty of Rehabilitation and Allied Health Sciences (FRAHS), Riphah International University Faisalabad, Pakistan
M SADIA College of Allied Health Sciences, Government College University Faisalabad, Pakistan
MR BUTT College of Allied Health Sciences, Government College University Faisalabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.695

Keywords:

HCC, Prognostic Biomarker, PIVKA-II, AFP, Diagnostic Accuracy

Abstract

The objective of this study was to evaluate the diagnostic accuracy of PIVKA-II as compared to AFP for the detection of hepatocellular carcinoma (HCC) and its potential as a devoid prognostic biomarker. With genomic discoveries, including gene mutations, epigenetic alterations, and non-coding RNAs, the context around HCC biomarkers has increased. The relevance of prognostic and predictive biomarkers is growing as they support treatment choices and evaluate clinical outcomes. These indicators are significant tools in enhancing patient care because they improve diagnosis, direct therapy, forecast outcomes, and evaluate treatment responses. Comprehensive information on the predictive value of several markers, however, is still lacking. In this study, 85 people took part, including those older than 18 with hepatocellular carcinoma in a range of clinical stages. Three groups represented the study population, comprising 85 individuals in total: group 1 consisted solely of patients with HCC, group 2 included patients with benign liver disease, and group 3 was designated as the control group. A male predominance is found in groups, except group 2. The quantity of PIVKA-II in serum was measured using an automated analyzer that was based on the CMIA. The immunoassay method was applied to determine the concentration of AFP. The statistical analyses of PIVKA-II and AFP consisted of sensitivity 90–99% and 58–81%, specificity 68–99%, and 61–98% with a 95% CI, respectively. The findings emphasize PIVKA-II's superior performance as a biomarker of cancer response when compared to AFP.

Downloads

Download data is not yet available.

References

Desai, S., and Guddati, A. K. (2023). Carcinoembryonic antigen, carbohydrate antigen 19-9, cancer antigen 125, prostate-specific antigen and other cancer markers: a primer on commonly used cancer markers. World Journal of Oncology 14, 4.

Duffy, M. J., and Crown, J. (2008). A personalized approach to cancer treatment: how biomarkers can help. Clinical chemistry 54, 1770-1779.

Gentile, I., Buonomo, A. R., Scotto, R., Zappulo, E., Carriero, C., Piccirillo, M., Izzo, F., Rizzo, M., Cerasuolo, D., and Borgia, G. (2017). Diagnostic accuracy of PIVKA-II, alpha-fetoprotein and a combination of both in diagnosis of hepatocellular carcinoma in patients affected by chronic HCV infection. in vivo 31, 695-700.

Gonzalez-Angulo, A. M., Hennessy, B. T., and Mills, G. B. (2010). Future of personalized medicine in oncology: a systems biology approach. Journal of clinical oncology 28, 2777.

Huang, S., Jiang, F., Wang, Y., Yu, Y., Ren, S., Wang, X., Yin, P., and Lou, J. (2017). Diagnostic performance of tumor markers AFP and PIVKA-II in Chinese hepatocellular carcinoma patients. Tumor Biology 39, 1010428317705763.

Koulouris, A., Tsagkaris, C., Spyrou, V., Pappa, E., Troullinou, A., and Nikolaou, M. (2021). Hepatocellular carcinoma: an overview of the changing landscape of treatment options. Journal of hepatocellular carcinoma, 387-401.

Liebman, H. A., Furie, B. C., Tong, M. J., Blanchard, R. A., Lo, K.-J., Lee, S.-D., Coleman, M. S., and Furie, B. (1984). Des-γ-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. New England Journal of Medicine 310, 1427-1431.

Mittal, S., and El-Serag, H. B. (2013). Epidemiology of HCC: consider the population. Journal of clinical gastroenterology 47, S2.

Parthasarathy, S., Soundararajan, P., Sakthivelu, M., Karuppiah, K. M., Velusamy, P., Gopinath, S. C., and Pachaiappan, R. (2023). The role of prognostic biomarkers and their implications in early detection of preeclampsia: A systematic review. Process Biochemistry.

Prabhakar, T., Kaushal, K., Prasad, M., Gupta, E., Sood, A., Jain, A. K., Shukla, A., Goel, A., Duseja, A., and Saraya, A. (2023). Etiologic fractions in patients of hepatocellular carcinoma in India with and without a background of cirrhosis: a multi-centric study. Hepatology International 17, 745-752.

Reig, M., Forner, A., Rimola, J., Ferrer-Fàbrega, J., Burrel, M., Garcia-Criado, Á., Kelley, R. K., Galle, P. R., Mazzaferro, V., and Salem, R. (2022). BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update. Journal of hepatology 76, 681-693.

Riley, R., Sauerbrei, W., and Altman, D. (2009). Prognostic markers in cancer: the evolution of evidence from single studies to meta-analysis, and beyond. British journal of cancer 100, 1219-1229.

Sadler, L., Jones, H., Whiting, P., Rogers, M., Watt, K., Cramp, M., Ryder, S., Stein, K., Welton, N., and Oppe, F. (2023). Diagnostic accuracy of serological and imaging tests used in surveillance for hepatocellular carcinoma in adults with cirrhosis: a systematic review protocol. NIHR Open Research 3, 23.

Sagar, V. M., Herring, K., Curbishley, S., Hodson, J., Fletcher, P., Karkhanis, S., Mehrzad, H., Punia, P., Shah, T., and Shetty, S. (2021a). The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma.

Sagar, V. M., Herring, K., Curbishley, S., Hodson, J., Fletcher, P., Karkhanis, S., Mehrzad, H., Punia, P., Shah, T., and Shetty, S. (2021b). The potential of PIVKA-II as a treatment response biomarker in hepatocellular carcinoma: A prospective United Kingdom cohort study. Oncotarget 12, 2338.

Steinmann, S. M., Sánchez-Martín, A., Tanzer, E., Cigliano, A., Pes, G. M., Simile, M. M., Desaubry, L., Marin, J. J., Evert, M., and Calvisi, D. F. (2023). eIF4A1 is a prognostic marker and actionable target in human hepatocellular carcinoma. International Journal of Molecular Sciences 24, 2055.

Su, T.-H., Peng, C.-Y., Chang, S.-H., Tseng, T.-C., Liu, C.-J., Chen, C.-L., Liu, C.-H., Yang, H.-C., Chen, P.-J., and Kao, J.-H. (2022). Serum PIVKA-II and alpha-fetoprotein at virological remission predicts hepatocellular carcinoma in chronic hepatitis B related cirrhosis. Journal of the Formosan Medical Association 121, 703-711.

Sun, H., Yang, W., Zhou, W., Zhou, C., Liu, S., Shi, H., and Tian, W. (2023). Prognostic value of des‑γ‑carboxyprothrombin in patients with AFP‑negative HCC treated with TACE. Oncology Letters 25, 1-13.

Suttichaimongkol, T., Mitpracha, M., Tangvoraphonkchai, K., Sadee, P., Sawanyawisuth, K., and Sukeepaisarnjaroen, W. (2023). PIVKA-II or AFP has better diagnostic properties for hepatocellular carcinoma diagnosis in high-risk patients. Journal of Circulating Biomarkers 12, 12.

Villalba-López, F., Sáenz-Mateos, L. F., Sánchez-Lorencio, M. I., De La Orden-García, V., Alconchel-Gago, F., Cascales-Campos, P. A., García-Bernardo, C., Noguera-Velasco, J. A., Baroja-Mazo, A., and Ramírez-Romero, P. (2023). Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma. Scientific Reports 13, 5621.

Xu, F., Zhang, L., He, W., Song, D., Ji, X., and Shao, J. (2021). The diagnostic value of serum PIVKA-II alone or in combination with AFP in Chinese hepatocellular carcinoma patients. Disease markers 2021, 1-9.

Zhao, Y.-J., Ju, Q., and Li, G.-C. (2013). Tumor markers for hepatocellular carcinoma. Molecular and clinical oncology 1, 593-598.